贝伐联合奥沙利铂、卡培他滨治疗晚期结肠癌的疗效研究  

Study on the Efficacy of Beva Combined with Oxaliplatin and Capecitabine in the Treatment of Advanced Colon Cancer

作　　者：唐鸣[1] 唐小慧[1] TANG Ming;TANG Xiaohui(Department of Oncology,Qidong People's Hospital,Qidong,Jiangsu Province,226200 China)

机构地区：[1]江苏省启东市人民医院肿瘤内科,江苏启东226200

出　　处：《世界复合医学》2021年第10期187-190,共4页World Journal of Complex Medicine

摘　　要：目的探究晚期结肠癌患者接受贝伐联合奥沙利铂、卡培他滨治疗的临床疗效。方法84例观察对象选自该科室2018年5月—2021年5月接收的晚期结肠癌患者,以数表法对这84例患者实施随机分组,42例接受奥沙利铂、卡培他滨治疗患者纳入对照组,42例接受贝伐联合奥沙利铂、卡培他滨治疗患者纳入观察组,对比患者血清肿瘤物浓度、病情缓解情况,观察患者不良反应与生活质量变化。结果观察组治疗后血清肿瘤物浓度均低于对照组,差异有统计学意义(P<0.05);经联合治疗,观察组总缓解率高达54.76%,明显高于对照组,差异有统计学意义(χ^(2)=4.861,P<0.05);观察组经治疗,患者发生胃肠道反应等不良反应共5例,发生率为11.90%,明显少于对照组,差异有统计学意义(χ^(2)=5.509,P<0.05);对比两组Spitzer指数,观察组从精神状况、健康状况、日常生活等5个方面看,生活质量均优于对照组,差异有统计学意义(P<0.05)。结论晚期结肠癌患者经贝伐联合奥沙利铂、卡培他滨治疗,对患者体内血清肿瘤标志物浓度具有良好的调整作用,治疗有效性与安全性明显强于奥沙利铂与卡培他滨治疗方案。Objective To explore the clinical efficacy of beva combined with oxaliplatin and capecitabine in patients with advanced colon cancer.Methods Eighty-four observation subjects were selected from patients with advanced colon cancer accepted by the department from May 2018 to May 2021,and these 84 patients were randomly grouped using a digital table method.Forty-two patients who received oxaliplatin and capecitabine were included in the control group,and 42 patients who received bevac combined with oxaliplatin and capecitabine were included in the observation group.Compared the patient's serum tumor concentration and disease remission,observe the patient's adverse reactions and changes in the quality of life.Results After treatment,the serum tumor concentration of observation group was lower than that of control group,the difference was statistically significant(P<0.05);after combined treatment,the total remission rate in the observation group was 54.76%,significantly higher than that in the control group,the difference was statistically significant(χ^(2)=4.861,P<0.05);after treatment,there were 5 cases of gastrointestinal reaction and other adverse reactions in the observation group,the incidence was 11.90%,which was significantly lower than that in the control group,the difference was statistically significant(χ^(2)=5.509,P<0.05).The Spitzer index of the observation group was compared with that of the control group in terms of mental status,health status and daily life,and the quality of life of the observation group was better than that of the control group,the difference was statistically significant(P<0.05).Conclusion The treatment of patients with advanced colon cancer with bevac combined with oxaliplatin and capecitabine has a good adjustment effect on the serum tumor marker concentration in the patient.The effectiveness and safety of treatment are significantly stronger than that of oxaliplatin and capecitabine.

关 键 词：晚期结肠癌 化疗药物 免疫缺陷 协同作用 抗肿瘤血管 

分 类 号：R4[医药卫生—临床医学]